摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(4-(4-(4-methoxyphenyl)piperazin-1-yl)butoxy)-2,3-dihydrocyclo-penta[c]chromen-4(1H)-one | 1352122-51-0

中文名称
——
中文别名
——
英文名称
7-(4-(4-(4-methoxyphenyl)piperazin-1-yl)butoxy)-2,3-dihydrocyclo-penta[c]chromen-4(1H)-one
英文别名
7-{4-[4-(4-methoxyphenyl)piperazin-1-yl]butoxy}2,3-dihydro-1H-cyclopentene[c]benzopyran-4-one;7-{4-[4-(4-methoxyphenyl)piperazin-1-yl]butoxy}-2,3-dihydro-1H-cyclopenta[c]benzopyran-4-one;7-[4-[4-(4-methoxyphenyl)piperazin-1-yl]butoxy]-2,3-dihydro-1H-cyclopenta[c]chromen-4-one
7-(4-(4-(4-methoxyphenyl)piperazin-1-yl)butoxy)-2,3-dihydrocyclo-penta[c]chromen-4(1H)-one化学式
CAS
1352122-51-0
化学式
C27H32N2O4
mdl
——
分子量
448.562
InChiKey
RSKSIJANDNDTDQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    91-93 °C
  • 沸点:
    644.7±55.0 °C(predicted)
  • 密度:
    1.25±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    33
  • 可旋转键数:
    8
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    51.2
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics
    摘要:
    In this paper, we report the synthesis of novel, potential antipsychotic coumarin derivatives combining potent dopamine D-2, D-3 and serotonin 5-HT1A 5-HT(2)A receptors properties. We describe the structure activity relationship that leads us to the promising derivative: 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl) piperidin-1-yl)butoxy)-6-methyl-2,3-dihydrocyclopenta[c]chromen-4(1H)-one 27. The unique pharmacological features of compound 27 are a high affinity for dopamine D-2, D-3 and serotonin 5-HT1A, 5-HT2A receptors, together with a low affinity for H-1 receptor (to reduce the risk of obesity under chronic treatment). In animal models, compound 27 inhibited apomorphine-induced climbing and MK-801-induced hyperactivity without observable catalepsy at the highest dose tested. In particular, compound 27 was more potent than clozapine. (C) 2014 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2014.01.012
点击查看最新优质反应信息

文献信息

  • ALICYCLIC[C] BENZOPYRONE DERIVATIVES AND USES THEREOF
    申请人:Zhang Guisen
    公开号:US20140171442A1
    公开(公告)日:2014-06-19
    Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED 50 is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED 50 is higher and therapeutic index is greater in animal models of catalepsy.
    本发明涉及螺环[c]苯并吡喃衍生物及其用途。螺环[c]苯并吡喃衍生物是由式I所表示的化合物或其盐。本化合物不仅显著改善了MK-801引起的高活性,而且有效地改善了阿泼吗啉引起的攀爬症状,并且在有效剂量范围内不会引起EPS。这些体外靶点和体内药理模型与因多巴胺功能障碍引起的神经系统疾病密切相关,特别是精神分裂症。因此,本化合物可用于治疗中枢神经系统疾病,特别是精神分裂症。在两种动物模型即MK-801引起的高活性和阿泼吗啉引起的攀爬症状中,ED50更低,效果更强,而在病理模型的动物模型中,ED50更高,治疗指数更大。
  • ALICYCLIC[C]BENZOPYRONE DERIVATIVES AND USES THEREOF
    申请人:Huazhong University of Science and Technology
    公开号:EP2746269A1
    公开(公告)日:2014-06-25
    Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED50 is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED50 is higher and therapeutic index is greater in animal models of catalepsy.
    公开了脂环族[c]苯并吡喃酮衍生物及其用途。脂环族[c]苯并吡喃酮衍生物为式 I 所代表的化合物或其盐类。本化合物不仅能明显改善 MK-801 诱导的高活性,还能有效改善阿朴吗啡诱发的攀爬症状,并且在有效剂量内不会引起 EPS。这些体外靶点和体内药理模型与多巴胺功能障碍引起的神经系统疾病,尤其是精神分裂症密切相关。因此,本化合物可用于治疗中枢神经系统疾病,尤其是精神分裂症。在两种动物模型(即 MK-801 诱导的高活性和阿朴吗啡诱发的攀爬症状)中,ED50 较低,效果较强;而在催眠动物模型中,ED50 较高,治疗指数较大。
  • ALICYCLIC [C]BENZOPYRONE DERIVATIVES AND USES THEREOF
    申请人:Huazhong University of Science and Technology
    公开号:EP2746269B1
    公开(公告)日:2016-01-20
  • US9018213B2
    申请人:——
    公开号:US9018213B2
    公开(公告)日:2015-04-28
  • Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics
    作者:Yin Chen、Yu Lan、Songlin Wang、Heng Zhang、Xiangqing Xu、Xin Liu、Minquan Yu、Bi-Feng Liu、Guisen Zhang
    DOI:10.1016/j.ejmech.2014.01.012
    日期:2014.3
    In this paper, we report the synthesis of novel, potential antipsychotic coumarin derivatives combining potent dopamine D-2, D-3 and serotonin 5-HT1A 5-HT(2)A receptors properties. We describe the structure activity relationship that leads us to the promising derivative: 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl) piperidin-1-yl)butoxy)-6-methyl-2,3-dihydrocyclopenta[c]chromen-4(1H)-one 27. The unique pharmacological features of compound 27 are a high affinity for dopamine D-2, D-3 and serotonin 5-HT1A, 5-HT2A receptors, together with a low affinity for H-1 receptor (to reduce the risk of obesity under chronic treatment). In animal models, compound 27 inhibited apomorphine-induced climbing and MK-801-induced hyperactivity without observable catalepsy at the highest dose tested. In particular, compound 27 was more potent than clozapine. (C) 2014 Elsevier Masson SAS. All rights reserved.
查看更多